Globus Medical, Inc.

NYSE:GMED Rapport sur les actions

Capitalisation boursière : US$9.7b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Globus Medical Gestion

Gestion contrôle des critères 4/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Dan Scavilla

Directeur général

US$4.6m

Rémunération totale

Pourcentage du salaire du PDG10.2%
Durée du mandat du directeur général2.3yrs
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction5.3yrs
Durée moyenne du mandat des membres du conseil d'administration5.3yrs

Mises à jour récentes de la gestion

Recent updates

Globus Medical: A Post Acquisition Analysis

Aug 26

Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors

Jun 28
Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors

An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Apr 08
An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly

Mar 20
Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly

Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock

Feb 27

Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?

Feb 09
Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?

Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings

Jan 17
Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings

Globus Medical: Merger Overhang Lingering

Nov 27

Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?

Nov 14
Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?

Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?

Oct 27
Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?

Globus Medical: Almost Having My Back

Sep 13

Globus Medical: Slightly Too Pricey Right Now

Aug 07

Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy

Jul 18

Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?

Jul 11
Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?

Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching

Jun 18
Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Apr 09
Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?

Mar 22
What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?

Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?

Feb 24
Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?

Globus Medical Q4 2022 Earnings Preview

Feb 20

Globus Medical: An Impressive Long-Term Revenue Growth Play

Jan 08

Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

Dec 22
Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends

Dec 01
Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends

Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line

Nov 08

A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)

Oct 15
A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)

Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact

Sep 02

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Sep 02
Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?

Aug 11
Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?

Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective

Jun 05

Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital

May 24
Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital

Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

May 06
Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

Analyse de la rémunération des PDG

Comment la rémunération de Dan Scavilla a-t-elle évolué par rapport aux bénéfices de Globus Medical?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

US$41m

Mar 31 2024n/an/a

US$67m

Dec 31 2023US$5mUS$464k

US$123m

Sep 30 2023n/an/a

US$158m

Jun 30 2023n/an/a

US$204m

Mar 31 2023n/an/a

US$201m

Dec 31 2022US$4mUS$437k

US$190m

Sep 30 2022n/an/a

US$155m

Jun 30 2022n/an/a

US$155m

Mar 31 2022n/an/a

US$142m

Dec 31 2021US$2mUS$396k

US$149m

Sep 30 2021n/an/a

US$187m

Jun 30 2021n/an/a

US$184m

Mar 31 2021n/an/a

US$122m

Dec 31 2020US$2mUS$384k

US$102m

Sep 30 2020n/an/a

US$95m

Jun 30 2020n/an/a

US$89m

Mar 31 2020n/an/a

US$148m

Dec 31 2019US$2mUS$366k

US$155m

Sep 30 2019n/an/a

US$146m

Jun 30 2019n/an/a

US$143m

Mar 31 2019n/an/a

US$150m

Dec 31 2018US$2mUS$355k

US$156m

Sep 30 2018n/an/a

US$144m

Jun 30 2018n/an/a

US$134m

Mar 31 2018n/an/a

US$118m

Dec 31 2017US$1mUS$345k

US$107m

Rémunération vs marché: La rémunération totale de Dan ($USD 4.56M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 8.39M ).

Rémunération et revenus: La rémunération de Dan a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Dan Scavilla (59 yo)

2.3yrs

Titularisation

US$4,564,374

Compensation

Mr. Daniel T. Scavilla, also known as Dan, serves as President and Chief Executive Officer at Globus Medical, Inc. since April 21, 2022 and serves as its Director since April 2022. He had been Executive Vi...


Équipe de direction

NomPositionTitularisationCompensationPropriété
David Paul
Co-Founder & Executive Chairman21.6yrsUS$3.22m16.44%
$ 1.6b
Daniel Scavilla
President2.3yrsUS$4.56mpas de données
Keith Pfeil
CFO & COO5yrsUS$2.06m0%
$ 0
Kelly Huller
Senior VP5.7yrsUS$1.64m0%
$ 0
Brian Kearns
Senior Vice President of Business Development & Investor Relationsno datapas de donnéespas de données

5.3yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe de direction de GMED est chevronnée et expérimentée (ancienneté moyenne 5.3 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
David Paul
Co-Founder & Executive Chairman21.6yrsUS$3.22m16.44%
$ 1.6b
Daniel Scavilla
President2.3yrsUS$4.56mpas de données
Ann Rhoads
Independent Director13.1yrsUS$490.69k0.017%
$ 1.6m
John DeFord
Independent Directorless than a yearUS$276.27k0.011%
$ 1.1m
Stephen Zarrilli
Independent Director5.3yrsUS$470.69k0%
$ 0
James Tobin
Independent Director9yrsUS$478.19k0%
$ 0
Daniel Wolterman
Independent Directorless than a yearUS$278.15k0.018%
$ 1.7m
Robert Douglas
Independent Director4.7yrsUS$470.69k0.0015%
$ 144.0k
David Davidar
Independent Director21.4yrsUS$468.19k0.57%
$ 55.5m
Leslie Norwalk
Independent Directorless than a yearUS$278.77k0.012%
$ 1.2m
Daniel Lemaitre
Independent Director13.3yrsUS$478.19k0%
$ 0

5.3yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de GMED sont considérés comme expérimentés (ancienneté moyenne 5.3 ans).